China is changing how healthcare works, and whole exome sequencing (WES) is playing a big role in that shift.
This technology focuses on decoding the most important part of human genes, helping doctors make faster and more accurate decisions.
In 2024, the China whole exome sequencing market stood at around $26 million.
Experts expect it to reach nearly $103.9 million by 2030, growing at a strong 27.3% CAGR.
China Is Growing Faster Than the Global Market
China is not just growing, it is growing faster than most countries in genomics.
The global WES market is expanding at around 18.4% CAGR, but China is moving much faster.
This growth comes from real changes happening in the system.
More hospitals are adopting advanced technologies, and the government is pushing precision medicine programs strongly.
Different Reports, Same Direction; Rapid Growth
Market estimates may vary, but the growth direction is clear and strong.
Multiple projections show aggressive expansion across the next decade.
Some estimates show:
- 2024 market size: $26 million
- 2030 projection: $103.9 million
- Growth rate: 27.3% CAGR
Other long-term projections suggest:
- 2024 estimate: ~$151 million
- 2035 projection: $1.14 billion
- CAGR: ~20.2%
Another outlook indicates:
- 2024: ~$350 million
- 2032: ~$1.42 billion
- CAGR: ~19.2%
Even with different numbers, all data points to one thing—fast and steady growth.
Consumables Lead the Market Today
Consumables like kits and reagents dominate the market right now.
They held more than 74% share in 2024.
This happens because every sequencing process needs these materials again and again.
So companies earn repeated revenue instead of one-time sales.
Services Are Growing Even Faster
While consumables lead today, services are becoming the fastest-growing part.
Data analysis and interpretation are now essential in sequencing.
WES produces large and complex data sets.
That is why demand for bioinformatics and expert support is increasing quickly.
Applications Are Expanding Beyond Research
Earlier, WES was mainly used in research labs.
Now, hospitals are using it in daily clinical work.
It is helping in diagnosing diseases faster and more accurately.
Doctors can now identify genetic problems and choose better treatments.
Some key application areas include:
- Clinical diagnostics
- Drug discovery and development (~47% global share)
- Rare disease detection
- Cancer genomics
This shift is making WES more important in real patient care.
Looking for FREE expert guidance in this market? Get in touch; we’re just a message away: [https://www.towardshealthcare.com/contact-us]
Technology Is Making Sequencing Better and Faster
Sequencing by synthesis is the most widely used technology today.
It holds nearly 73% market share.
This method offers better accuracy and faster results.
It also reduces the cost per test, making it more practical for hospitals.
Data Interpretation Is the Real Challenge Now
Sequencing itself is no longer the hardest step.
Understanding the data has become the bigger challenge.
The market is now seeing growth in AI-based tools and cloud platforms.
There is also a rising need for skilled professionals who can interpret genetic data.
Who Is Using Whole Exome Sequencing the Most?
Different sectors are driving demand in different ways.
Research institutes still hold a large share, but hospitals are catching up fast.
Pharma and biotech companies are also using WES for innovation.
They rely on it to develop targeted therapies and new drugs.
Strong Competition Between Global and Local Players
The Chinese market includes both global companies and local leaders.
This mix is increasing competition and innovation.
Companies like BGI Group, Illumina, Thermo Fisher Scientific, Agilent Technologies, and Oxford Nanopore are active in this space.
Local players are focusing on reducing costs and improving access.
Whole Exome vs Whole Genome Sequencing
Whole genome sequencing is growing faster, but WES still holds strong value.
It offers a balance between cost and useful insights.
China’s whole genome sequencing market is projected to grow from $129.3 million in 2024 to $603.2 million by 2030, at a 31.2% CAGR.
Even then, many hospitals prefer WES.
It is faster, more affordable, and easier to use for clinical decisions.
What Is Driving This Growth?
Several key factors are pushing the market forward.
These are long-term drivers, not short-term trends.
- Rising cases of cancer and genetic diseases
- Growing awareness of early diagnosis
- Government support for precision medicine
- Falling sequencing costs
- Increasing adoption in hospitals
All these factors are working together to expand the market quickly.
Challenges Still Exist
Despite strong growth, the market still faces some issues.
These challenges can slow down adoption if not handled properly.
There is a shortage of skilled professionals in bioinformatics.
Data privacy and regulations are also becoming important concerns.
Rural areas still have limited access to advanced technologies.
And data interpretation costs remain high.
The Future Is Personalized Healthcare
China’s WES market is moving toward personalized treatment.
Healthcare is slowly becoming more predictive and precise.
Doctors are starting to use genetic data to guide treatments.
This approach improves outcomes and reduces trial-and-error methods.
Final Thought
The China whole exome sequencing market is not just growing in numbers.
It is changing how healthcare decisions are made.
From $26 million today to over $100 million by 2030, and possibly crossing $1 billion in the coming years, the growth is clear.
But beyond the numbers, the real impact lies in better diagnosis, better treatment, and better patient outcomes.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare Web Wire is a Part of Towards Healthcare, which is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04